[A26-48] Olipudase alfa (acid sphingomyelinase deficiency) – Benefit assessment according to §35a Social Code Book V
Last updated 03.08.2026
Project no.:
A26-48
Commission:
Commission awarded on 04.05.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) in paediatric and adult patients with type A/B or type B
Hint of a non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-48
| Project no. | Title | Status |
|---|---|---|
| G22-33 | Olipudase alfa (ASMD) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |